References
- Norlin JM, Calara PS, Schmitt-Egenolf, Real-world outcomes in 2646 psoriasis patients: one in five has PASI ≥10 and/or DLQI ≥10 under ongoing systemic therapy. J Dermatolog Treat. 2017;28:500–504.
- Gelfand JM, Wan J, Callis Duffin K, et al. Comparative effectiveness of commonly used systemic treatments or phototherapy for moderate to severe plaque psoriasis in the clinical practice setting. Arch Dermatol. 2012;148:487–94.
- Armstrong AW, Siegel MP, Bagel J, et al. From the Medical Board of the National Psoriasis Foundation: Treatment targets for plaque psoriasis. J Am Acad Dermatol. 2017;76:290–8.
- West C, Narahari S, O'Neill J, et al. Adherence to adalimumab in patients with moderate to severe psoriasis. Dermatol Online J. 2013;19:18182.